Source: Annual Congress 2009 - Pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. M. F. Berger, M. Beghetti, R. J. Barst, X. Jais, P. Acar, A. Fraisse, D. D. Ivy, I. Schulze-Neick, D. Bonnet, S. G Haworth (Groningen, Netherlands; Geneva, Switzerland; New York, Denver, United States Of America; Clamart, Toulouse, Marseille, Paris, France; London, United Kingdom). Longer-term survival in paediatric patients with idiopathic or familial pulmonary arterial hypertension treated with bosentan. Eur Respir J 2009; 34: Suppl. 53, 3886

Member's Comments

No comment yet.

Related content which might interest you: Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH) Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Efficacy and safety of oral bosentan in patients with Down‘s syndrome and pulmonary arterial hypertension due to congenital heart disease Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Long-term riociguat treatment towards implementing a targeted treatment strategy in patients with idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 Results of a 12-week outpatient cardiovascular rehabilitation in patients with idiopathic pulmonary arterial hypertension (iPAH) Source: Annual Congress 2008 - Pulmonary arterial hypertension and other pulmonary vascular diseases Year: 2008 Effect of long-term specific therapy in a cohort of 33 patients with pulmonary arterial hypertension of various etiologies Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 IgG4-related disease in pulmonary arterial hypertension on long-term epoprostenol treatment Source: Eur Respir J 2014; 43: 1516-1519 Year: 2014 Survival with first-line bosentan in patients with primary pulmonary hypertension. Source: Eur Respir J 2005; 25: 942 Year: 2005 Differential response to the addition of sildenafil to bosentan monotherapy between idiopathic and scleroderma-associated pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006 Survival in idiopathic pulmonary arterial hypertension Source: Annual Congress 2010 - Pulmonary circulation III Year: 2010 Charactaristics and prognosis of autoimmune antibody-positive patients of idiopathic pulmonary arterial hypertension Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study Source: ERJ Open Res, 4 (3) 00060-2018; 10.1183/23120541.00060-2018 Year: 2018 Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Comparison of clinical characteristics in patients with pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease Year: 2008 Long-term outcome of patients with portopulmonary hypertension treated with sildenafil Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006 Bosentan improves 6-minutes-walk-test in patients with inoperable chronic thrombo-embolic pulmonary hypertension (iCTEPH) Source: Eur Respir J 2005; 26: Suppl. 49, 272s Year: 2005 The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study Source: Eur Respir J 2006; 28: 138-143 Year: 2006 Safety and efficacy of immunoadsorption as an add-on to medical treatment in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Is survival in patients with severe group 3 pulmonary hypertension influenced by targeted therapy? Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015